Roivant Sciences Ltd. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Roivant Sciences Ltd. (Roivant) for the period ended September 30, 2025. Roivant is a biopharmaceutical company that operates through a portfolio of subsidiaries ("Vants") to develop and commercialize medicines. The company currently has no approved commercial products following the sale of Dermavant Sciences Ltd. to Organon in October 2024. Its primary focus is on advancing clinical-stage product candidates, including brepocitinib (Priovant), IMVT-1402 and batoclimab (Immunovant), and mosliciguat (Pulmovant).
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2025 |
|---|---|---|
| Revenue | $1.6 million | $3.7 million |
| Net Loss (Attributable to Roivant) | $(113.5) million | $(336.9) million |
| Operating Expenses | $307.8 million | $594.9 million |
| Research & Development (R&D) | $164.6 million | $317.5 million |
| General & Administrative (G&A) | $143.1 million | $277.1 million |
| Cash, Cash Equivalents & Marketable Securities | $4.4 billion (as of Sept 30, 2025) | |
| Accumulated Deficit | $429.1 million (as of Sept 30, 2025) |
Note: The company reported a significant unrealized gain on investments of $128.5 million for the quarter and $109.4 million for the six-month period, primarily driven by increases in the fair value of investments in Arbutus Biopharma and Datavant.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $2.9 million (65%) for the quarter and $8.7 million (70%) for the six months compared to the prior year periods. This is largely due to the absence of Dermavant revenue, which is now classified as discontinued operations.
- Increased R&D Spend: R&D expenses increased by $21.5 million for the quarter and $53.9 million for the six months. This reflects increased program-specific costs for the anti-FcRn franchise (Immunovant) and brepocitinib (Priovant), as well as higher personnel-related expenses.
- Decreased G&A Expenses: G&A expenses decreased by $59.8 million for the quarter and $25.6 million for the six months. The reduction is primarily attributed to lower one-time cash retention awards recognized in the prior year period under the 2024 Senior Executive Compensation Program, partially offset by an increase in share-based compensation.
- Investment Gains: The change in fair value of investments resulted in a gain of $128.5 million for the quarter, compared to $48.4 million in the prior year quarter, driven by public share price appreciation of Arbutus and valuation increases in Datavant.
- Share Repurchases: The company completed a $1.5 billion share repurchase program in June 2025. A new $500 million repurchase program was authorized in June 2025, with no purchases made under the new program as of September 30, 2025.
Guidance, Outlook, and Risks
Outlook and Catalysts: Management expects to incur significant operating losses for the foreseeable future. Key upcoming catalysts include:
- Brepocitinib (Priovant): NDA filing for dermatomyositis planned for the first half of 2026; Phase 3 topline data for non-infectious uveitis expected in the first half of 2027.
- Batoclimab (Immunovant): Topline data from Phase 3 trials in thyroid eye disease expected in the first half of 2026.
- Mosliciguat (Pulmovant): Phase 2 topline data for pulmonary hypertension expected in the second half of 2026.
Liquidity: With approximately $4.4 billion in cash and marketable securities, management believes current resources are sufficient to fund operations for the foreseeable future. However, the company may require additional capital in the future to fund operations, strategic transactions, or unforeseen circumstances.
Key Risks:
- Regulatory Uncertainty: Risks associated with FDA staffing reductions and potential government shutdowns impacting review timelines.
- Clinical Trial Outcomes: Failure of product candidates to demonstrate safety or efficacy in clinical trials.
- Intellectual Property: Ongoing litigation regarding lipid nanoparticle patents (Genevant/Arbutus vs. Moderna and Pfizer/BioNTech) and reliance on the HanAll Agreement for Immunovant's core IP.
- Third-Party Reliance: Dependence on third-party manufacturers and CROs for clinical and commercial supply.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $4.4 billion cash position against the current burn rate (approx. $390 million operating cash outflow for the six months ended Sept 30, 2025).
- Investment Valuation: Assess the volatility of the $128.5 million unrealized gain on investments (Arbutus and Datavant) and its impact on reported net loss.
- Clinical Timelines: Monitor the progress of the brepocitinib Phase 3 trials and the batoclimab Phase 3 thyroid eye disease studies against the stated 2026/2027 timelines.
- Share Repurchase Activity: Track execution of the new $500 million share repurchase program authorized in June 2025.
- Legal Proceedings: Review updates on the Genevant/Arbutus patent litigation against Moderna and Pfizer/BioNTech, including the scheduled jury trial in March 2026.